Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMN3D72)

Drug Name

SL-172154 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD40L receptor (CD40)	TTN6Y9A	TNR5_HUMAN	Inhibitor	[2]
Leukocyte surface antigen CD47 (CD47)	TT28S46	CD47_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
CD40L receptor (CD40)	DTT	CD40	4.629	4.991	5.53	3.385

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Ovarian cancer

ICD Disease Classification

2C73

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
CD40L receptor (CD40)	DTT	CD40	4.61E-01	0.56	0.5

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04406623) Phase 1 Study of SL-172154 (SIRPalpha-Fc-CD40L) in Subjects With Ovarian Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Shattuck Labs.